- Home
- SEER vs GDL Comparison
SEER vs GDL Comparison
Compare SEER & GDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SEER | GDL |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.2M | 94.9M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | SEER | GDL |
|---|---|---|
| Price | $1.85 | $8.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 188.3K | 11.2K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.02% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,376,999.00 | N/A |
| Revenue This Year | $22.37 | N/A |
| Revenue Next Year | $30.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.11 | N/A |
| 52 Week Low | $1.62 | $7.65 |
| 52 Week High | $2.50 | $8.13 |
Technical Indicators
Market Signals| Indicator | SEER | GDL |
|---|---|---|
| Relative Strength Index (RSI) | 44.70 | 48.91 |
| Support Level | $1.80 | $8.42 |
| Resistance Level | $1.88 | $8.49 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 47.37 | 51.98 |
Price Performance
Historical ComparisonAbout SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.